Current controversies surrounding liver transplantation for hepatocellular carcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 7, 2010, Pages 1217-1226

  Silva, Mauricio F ^a,c,d   Wigg, Alan J ^a,b  

^a FLINDERS UNIVERSITY   (Australia)

^b FLINDERS MEDICAL CENTRE   (Australia)

^c UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

^d Transplant Group Hospital   (Brazil)

Author keywords

downstaging; expanded criteria; HCC MELD; hepatocellular carcinoma; liver transplantation; locoregional therapy; selection criteria

Indexed keywords

CANCER STAGING; CLINICAL PRACTICE; HOSPITAL ADMISSION; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LIVING DONOR; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; TUMOR VOLUME; CARCINOMA, HEPATOCELLULAR; DONOR; DONOR SELECTION; EVIDENCE BASED MEDICINE; LIVER NEOPLASMS; PATHOLOGY; SUPPLY AND DISTRIBUTION; TIME; TREATMENT OUTCOME; RESOURCE ALLOCATION;

CARCINOMA, HEPATOCELLULAR; DONOR SELECTION; EVIDENCE-BASED MEDICINE; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEOPLASM STAGING; PATIENT SELECTION; TIME FACTORS; TISSUE DONORS; TREATMENT OUTCOME; WAITING LISTS;

EID: 77954019743     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06335.x     Document Type: Review

References (98)

1. Pankin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005 55 : 74 108.
2. KEW MC. Hepatic tumors and cysts. In : Feldmen M, Sleisenger MH, Schrschimidt BF, eds. Sleisenger & Fordtran'sn Gastrointestinal and Liver disease: Pathology/Diagnosis/Management, Vol. 1, 6th edn.
3. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005 42 : 1208 1236.
4. Penn I. Hepatic transplantation for primary and metastic cancers of the liver. Surgery 1991 110 : 726 734.
5. Iwatsuki S, Gordon RD, Shaw BW Jr., Starzl TE. Role of liver transplantation in cancer therapy. Ann. Surg. 1985 202 : 401 407.
6. Bismuth H, Castaing D, Ericzon BG et al. Hepatic transplantation in Europe. First report of the European Liver Transplant Registry. Lancet 1987 2 : 674 676.
7. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Eng. J. Med. 1996 334 : 693 699.
8. Herrero JI, Sangro B, Quiroga J et al. Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma. Liver Transpl. 2001 7 : 631 636.
9. Yao FY, Ferrell L, Bass NM et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001 33 : 1394 1403.
10. Roayaie S, Frischer J, Emre SH et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann. Surg. 2002 235 : 533 539.
11. Khakhar A, Solano E, Stell D et al. Survival after liver transplantation for hepatocellular carcinoma. Transplant. Proc. 2003 35 : 2438 2441.
12. Marsh JW, Dvorchik I. Liver organ allocation for hepatocellular carcinoma: are we sure? Liver Transpl. 2003 9 : 693 696.
13. Decaens T, Roudot-Thoraval F, Hadni-Bresson S et al. Impact of UCLA criteria according to pre-and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. Liver Transpl. 2006 12 : 1761 1769.
14. Onaca N, Gary LD, Goldstein RM, Jennings LW, Klintmalm GB. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transpl. 2007 13 : 391 399.
15. Parfitt JR, Marotta P, Alghamdi M et al. Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence. Liver Transpl. 2007 13 : 543 551.
16. Duffy JP, Vardanian A, Benjamin E et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-Year experience with 467 patients at UCLA. Ann. Surg. 2007 246 : 502 509.
17. Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NR, Roberts JP. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am. J. Transpl. 2007 7 : 2587 2596.
18. Herrero JA, Sangro B, Pardo F et al. Liver transplantation in patients with hepatocellular carcinoma across Milan criteria. Liver Transpl. 2008 14 : 272 278.
19. Zheng SS, Xu X, Wu J et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation 2008 85 : 1726 1732.
20. Marelli L, Grasso A, Pleguezuelo M et al. Tumour size and differentiation in predicting recurrence of hepatocellular carcinoma after liver transplantation: external validation of a new prognostic score. Ann. Surg. Oncol. 2008 15 : 3503 3511.
21. Silva M, Moya A, Berenguer M et al. Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma. Liver Transpl. 2008 14 : 1449 1460.
22. Mazzaferro V, Llovet JM, Miceli R et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009 10 : 35 42.
23. Majno PE, Adan R, Bismuth H et al. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann. Surg. 1997 226 : 688 701.
24. Fix OK, Kerlan R, Hirose R et al. Five-year intention-to-treat outcome of down-staging of hepatocellular carcinoma prior to liver transplantation. Hepatology 2009 50 (4 Suppl. 305A.
25. Chapman WC, Majella Doyle MB, Stuart JE et al. Outcomes ofneoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann. Surg. 2008 248 : 617 625.
26. Ravaioli M, Grazi GL, Piscaglia F et al. Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am. J. Transpl. 2008 8 : 2547 2555.
27. De Luna W, Sze DY, Ahmed A et al. Transarterial chemoinfusion for hepatocellular carcinoma as downstaging therapy and a bridge toward liver transplantation. Am. J. Transpl. 2009 9 : 1158 1168.
28. Yao FY. Expanded criteria for hepatocellular carcinoma: down-staging with a view to liver transplantation - yes. Sem. Liver Dis. 2006 26 : 239 247.
29. Llovet JM, Schwartz M, Fuster J, Bruix J. Expanded Criteria for hepatocellular carcinoma through down-staging prior to liver transplantation: not yet there. Sem. Liver Dis. 2006 26 : 248 253.
30. Forner A, Vilana R, Ayuso C et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnosis criteria for hepatocellular carcinoma. Hepatology 2008 47 : 97 104.
31. Grasso A, Stigliano R, Morisco F et al. Liver transplantation and recurrent hepatocellular carcinoma: predictive value of nodule size in a retrospective and explants study. Transplantation 2006 81 : 1532 1541.
32. O'Malley ME, Takayama Y, Sherman M. Outcome of small (10-20 mm) arterial phase-enhancing nodules seen on triphasic liver CT in patients with cirrhosis or chronic liver disease. Am. J. Gastroenterol. 2005 100 : 1523 1528.
33. Freeman RB, Mithoefer A, Ruthazer R et al. Optimizing staging for hepatocellular carcinoma before liver transplantation: a retrospective analysis of the UNOS/OPTN database. Liver Transpl. 2006 12 : 1504 1511.
34. Burrel M, Llovet JM, Ayuso C et al. MRI angiography is superior to helicoidal CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 2003 38 : 1034 1042.
35. Shah SA, Tan JCC, McGilvray ID et al. Accuracy of staging as a predictor for recurrence after liver transplantation for hepatocellular carcinoma. Transplantation 2006 81 : 1633 1639.
36. Belefer AS, Hayashi PH, Di Bisceglie AM. Liver transplantation for hepatocellular carcinoma. Gastroenterology 2005 128 : 1752 1764.
37. Bruix J, Fuster J, Llovet J. Liver transplantation for hepatocellular carcinoma: foucault pendulum versus evidence-based decision. Liver Transpl. 2003 9 : 700 702.
38. Yao FY, Bass NM, Nicolai B et al. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle, and a dropout from the waiting list. Liver Transpl. 2002 8 : 873 883.
39. Shiffman RN, Shekelle P, Overhage JM, Slutzky J, Grimshaw J, Deshpand AM. Standardized reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardization. Ann. Intern. Med. 2003 139 : 493 498.
40. Woolf SH, Sox HC. The expert panel on preventive services: continuing the work of the U.S. preventive services task force. Am. J. Prev. Med. 1991 7 : 326 330.
41. Moher D, Dulberg CS, Wells GA. Statistical power, sample size, and their report in randomized controlled trials. JAMA 1994 272 : 122 124.
42. Kamath PS. The need for better clinical trials. Hepatology 2008 48 : 1 3.
43. LO CM, Fan ST, Liu CL, Chan SC, Wong J. The role and limitation of living donor liver transplantation for hepatocellular carcinoma. Liver Transpl. 2004 10 : 440 447.
44. Todo S, Furukawa H, Japanese Study Group on Organ Transplantation. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann. Surg. 2004 240 : 451 459.
45. Hwang S, Lee SG, Joe JW et al. Liver transplantation for adult patients with hepatocellular carcinoma in Korea: comparison between cadaveric donor and living donor liver transplantation. Liver Transpl. 2005 11 : 1265 1272.
46. Takada Y, Ueda M, Ito T et al. Living donor liver transplantation as a second-line therapeutic strategy for patients with hepatocellular carcinoma. Liver Transpl. 2006 12 : 912 919.
47. Malagó M, Sotiropoulos GC, Nadalin, S et al. Living donor liver transplantation for hepatocellular carcinoma: a single-centre preliminary report. Liver Transpl. 2006 12 : 934 940.
48. Sarasin FP, Majno PE, Llovet JM, Bruix J, Mentha G, Hadengue A. Living donor liver transplantation for early hepatocellular carcinoma: a life-expectancy and a cost-effectiveness perspective. Hepatology 2001 33 : 1073 1079.
49. Hiatt JR, Carmody IC, Bussutil RW. Should we expand the criteria for hepatocellular carcinoma with living-donor liver transplantation?-no-, never! J. Hepatol. 2005 43 : 573 577.
50. Broelsch CE, Frilling A, Malago M. Should we expand the criteria for hepatocellular carcinoma with living-donor liver transplantation?-yes-, of course! J. Hepatol. 2005 43 : 569 573.
51. Middleton J, Duffield M, Lynch S et al. Living donor liver transplantation - adult donor outcomes: a systematic review. Liver Transpl. 2006 12 : 24 30.
52. Brown RS, Russo MW, Lai M et al. A survey of liver transplantation from living adult donors in the United States. N. Eng. J. Med. 2003 348 : 818 885.
53. Beavers KL, Sandler RS, Shrestha R. Donor morbidity associated with right lobectomy for living donor liver transplantation to adult recipients: a systematic review. Liver Transpl. 2002 8 110 117.
54. Bruix J, Llovet JM. Prognostic prediction and treatment strategies in hepatocellular carcinoma. Hepatology 2002 35 : 519 524.
55. Lee SG, Hwang S, Moon DB et al. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transpl. 2008 14 : 935 945.
56. Erim Y, Beckmann M, Kroencke S et al. Psycological strain in urgent indications for living donor liver transplantation. Liver Transpl. 2007 13 : 886 895.
57. Ito T, Takada Y, Ueda M et al. Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation. Liver Transpl. 2007 13 : 1637 1644.
58. Soejima Y, Taketomi A, Yoshizumi T et al. Extended indication for living donor liver transplantation in patients with hepatocellular carcinoma. Transplantation 2007 83 : 893 899.
59. Cillo U, Vitale A, Bassanello M et al. Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann. Surg. 2004 239 : 150 159.
60. Hoshida Y, Villanueva A, Kobayashi M et al. Gene expressions in fixed tissues and outcome in hepatocellular carcinoma. N. Eng. J. Med. 2008 359 : 1995 2004.
61. Lee JS, Shu IS, Heo J et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004 40 : 667 676.
62. Schwartz M, Dvorchik I, Roayaie S et al. Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers. J. Hepatol. 2008 49 : 581 588.
63. Shirabe K, Itoh S, Yoshizumi Y et al. The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombin. J. Surg. Oncol. 2007 95 : 235 240.
64. Marubashi S, Dono K, Nagano H et al. Detection of AFP mRNA-expressing cells in the peripheral blood for prediction of hepatocellular carcinoma recurrence after living donor liver transplantation. Transpl. Int. 2007 20 : 576 582.
65. Cheung ST, Fan ST, Lee YT et al. Albumin mRNA in plasma predicts post-transplant recurrence in patients with hepatocellular carcinoma. Transplantation 2008 85 : 81 7.
66. Cillo U, Vitale A, Grigoletto F et al. Intention-to-treat analysis of liver transplantation in selected, aggressively treated HCC patients exceeding the Milan criteria. Am. J. Transpl. 2007 7 : 972 981.
67. Pawlik TM, Gleisner AL, Anders RA, Assumpcao L, Maley W, Choti MA. Preoperative assessment of hepatocellular carcinoma tumor grade using needle biopsy, implications for transplant eligibility. Ann. Surg. 2007 245 : 435 442.
68. Jonas S, Bechstein WO, Steinmmuler T et al. Vascular invasion and histopathologic grading determine after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001 33 : 1080 1086.
69. Otto G, Herber S, Heise M et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl. 2006 : 12 1260 1267.
70. Millonig G, Graziadei IW, Freud MC et al. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl. 2007 13 : 272 279.
71. Hanouneh I, Macaron C, Lopez R, Aucejo FN, Zein NN. Five-year intention-to-treat outcome of down-staging of hepatocellular carcinoma prior to liver transplantation. Hepatology 2009 50 (4 Suppl. 305A.
72. Llovet JM, Bustamante J, Castells A et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999 29 : 62 7.
73. Volk ML, Vijan S, Marrero JA. A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan Criteria. Am. J. Transpl. 2008 8 : 839 846.
74. Kamath PS, Wiesner RH, Malinchoc M et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001 33 : 464 470.
75. Austin MT, Poulose BK, Ray WA, Arbogast PG, Feure ID, Pinson CW. Moldel for end-stage liver disease: did the new liver allocation policy affect the waiting list mortality? Arch. Surg. 2007 142 : 1079 1085.
76. Moylan CA, Brady CW, Johnson JL, Smith AD, Tuttle-Newhall JE, Muir A. Disparities in liver transplantation before and after introduction of the MELD score. JAMA 2008 300 : 2371 2378.
77. Wiesner RH, Edwards E, Freeman RB et al. United network for organ sharing liver disease severity score committee. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003 124 : 91 6.
78. Roayaie K, Feng S. Allocation policy for hepatocellular carcinoma in the MELD era: room for improvement? Liver Transpl. 2007 13 : S36 43.
79. Sharma P, Balan V, Hernandez JL et al. Liver transplantation for hepatocellular carcinoma: the MELD impact. Liver Transpl. 2004 10 : 36 41.
80. Hayashi PH, Trotter JF, Forman L et al. Impact of transplant diagnosis of hepatocellular carcinoma on cadaveric liver allocation in the era of MELD score. Liver Transpl. 2004 1 : 42 8.
81. Freeman RB, Edwards EB, Harper AM. Waiting list removal rates among patients with chronic and malignant liver diseases. Am. J. Transpl. 2006 6 : 1416 1421.
82. Freeman RB, Steffick DE, Guidinger MK, Farmer DG, Berg CL, Merion RM. Liver and intestine transplantation in the United States, 1997-2006. Am. J. Transpl. 2008 8 : 958 976.
83. Washburn K. Model for end-stage liver disease and hepatocellular carcinoma: a moving target. Transpl. Rev. 2010 24 : 18 27.
84. Di Bisceglie AM. Pretransplant treatments for hepatocellular carcinoma: do they improve outcomes? Liver Transpl. 2005 11 : S10 13.
85. Lesurtel M, Mullhaupt B, Pestalozzi BC, Pfammatter T, Clevien PA. Transaterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma: an evidence-based analysis. Am. J. Transpl. 2006 6 : 2644 2650.
86. Mazzaferro V, Battiston C, Perrone S et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann. Surg. 2004 240 : 900 909.
87. Lu DS, Yu NC, Raman SS et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology 2005 41 : 1130 1137.
88. Lopez PM, Villanueva A, Roayaie S, Llovet JM. Neoadjuvant therapies for hepatocellular carcinoma before liver transplantation: a critical appraisal. Liver Transpl. 2006 12 : 1747 1754.
89. Ravaioli M, Grazi G, Luca G et al. Partial necrosis on hepatocellular carcinoma nodules facilitates tumor recurrence after liver transplantation. Transplantation 2004 12 : 1780 1786.
90. Belghiti J, Carr BI, Greig PD, Lencioni R, Poon RT. Treatment before liver transplantation for HCC. Ann. Surg. Oncol. 2008 15 : 993 1000.
91. Northup PG, Argo CK, Shah NL, Schmitt TM. Locoregional therapy of T1 hepatocellular carcinomas is associated with increased transplant waiting list mortality and offers no additional post-transplant survival. Hepatology 2009 50 (4 Suppl. 306A.
92. Yamashiki N, Gaynor J, Kato T et al. Competing risks analysis of predictors of delisting owing to tumor progression in liver transplantation candidates with hepatocellular carcinoma. Am. J. Transpl. 2004 4 : 774 781.
93. Llovet JM, Bruix J, Fuster J et al. Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power. Hepatology 1998 27 : 1572 1577.
94. Llovet JM, Mas X, Aponte JJ et al. Cost-effectiveness of adjuvant therapy for hepatocellucar carcinoma during the waiting list for liver transplantation. Gut 2002 50 : 123 128.
95. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Eng. J. Med. 2008 359 : 378 390.
96. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009 10 : 25 34.
97. Hoffman K, Glimm H, Radeleff B et al. Prospective, randomized, double-blind, multi-center, phase III clinical study on transarterial chemoembolization (TACE) combined with sorafenib versus TACE plus placebo in patients with hepatocellular carcinoma before liver transplantation. BMJ Cancer 2008 8 : 349 354.
98. Sandrousi C, Dawson LA, Lee M et al. Radiotherapy as a bridge to liver transplantation for hepatocellular carcinoma. Transpl. Int. 2009 23 : 299 306.